News

For the second quarter ended June 30, 2006, Abbott’s earnings were just over $612 million, down 30% on the previous year’s $877 million. However, the company’s diluted earnings

A six-month 1,195-patient trial named IDEAL showed that the Exelon patch (rivastigmine transdermal patch) provided benefits across a range of symptoms and that the target dose was well

In March 2006, Protiva filed a statement of claim in the Supreme Court of British Columbia against Inex Pharmaceuticals, Inex’ CEO, and three Inex directors who also served

Net sales of Fuzeon in the US and Canada for the second quarter of 2006 were $31.1 million, an increase of 23% over Q2 2005. Total worldwide net

The company in question, BioEden is registered with the FDA and claims to be the first tooth cell bank in the world to offer cellular isolation and storage

Professor Ashley Bush, of the Mental Health Research Institute of Victoria, Australia and co-founding scientist of Prana, presented data on PBT2 at the 10th International Conference on Alzheimer’s

A special protocol assessment (SPA) provides a mechanism for the FDA and sponsors to reach agreement on the design, size, execution and analysis of a clinical trial that

These compounds effectively inhibit JAK3 (janus kinase 3) dependent lymphocyte proliferation and are highly selective in an array of off-target assays. The compounds were discovered and characterized by

This is the first microbicide clinical development program specifically for prevention of genital herpes to be funded by the US National Institutes of Health (NIH). Starpharma also understands